>latest-news

Trecondyv® Moves Closer To Public Drug Plans After Medexus-pCPA Negotiation

Medexus Pharmaceuticals finalized a pan-Canadian Pharmaceutical Alliance agreement to fund Trecondyv® (treosulfan), enhancing Canadian patient access.

Breaking News

  • Nov 19, 2024

  • Simantini Singh Deo

Trecondyv® Moves Closer To Public Drug Plans After Medexus-pCPA Negotiation

Earlier in November 2024, Medexus Pharmaceuticals announced the successful conclusion of its negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) to enable public funding and patient access to Trecondyv® (treosulfan for injection) across Canada. The pCPA is an independent body comprising federal, provincial, and territorial governments.  


This achievement, finalized on November 4, 2024, resulted from a collaborative negotiation effort with the pCPA. It followed reimbursement recommendations issued earlier this year by Québec's Institut National d'Excellence en Santé et en Services Sociaux (March 6, 2024) and Canada's Drug Agency (formerly CADTH) (March 18, 2024), which were based on Medexus’s submissions from July 2023.  


Richard Labelle, Medexus's Chief Operating Officer, said in a statement, "We are very encouraged by this additional vote of confidence in treosulfan. Approximately three-quarters of transplant centers across Canada are already using treosulfan, consistent with the strong year-over-year unit demand growth we saw as of September 30, 2024. 


He further commented, “This latest development emphasizes the need to move quickly through the subsequent steps to public reimbursement of Trecondyv®, and is yet another important indicator of this product's prospects and potential, both in the Canadian market and, if and when approved by the FDA, the US market as well."


The final decisions regarding public reimbursement by individual government entities will be the next step of this process. Medexus remains committed to working and participating in provincial, territorial, and federal government organizations to help make Trecondyv® available through public drug plans as quickly as possible, providing crucial access to patients in need.


Dr Ivan Pasic, from Toronto's Princess Margaret Hospital, also mentioned, "Clinicians should always make the best choice possible for their patients, so we are very pleased with this new development, as it will hopefully result in greater physician access to this treatment option across Canada."

Ad
Advertisement